Mark Mynhier is a Principal at PricewaterhouseCoopers with over 25 years of experience in the provider, pharmaceutical, medical device, and molecular diagnostics industries. He works with Boards of Directors and senior executives on corporate transformation initiatives, including precision oncology therapy development, chronic care delivery in the community, product acquisitions, and business unit carve-outs.
Mark is the global general manager of the DoubleJump Interchange™, a PwC proprietary asset for which he is the patent holder in Japan, Korea, Singapore, Australia, South Africa, and Canada. This asset facilitates scientific collaboration and care delivery cooperation by providing strategic partners access to a cloud-based, highly secure, HIPAA-compliant, brokered health data hub with the ability to assemble targeted, high dimensional, longitudinal medical records and interrogate them using an integrated analytical pipeline to track treatment compliance, monitor therapy outcomes, and reveal research insights of interest. The DoubleJump Interchange™ is deployed in the United States and Japan.
Mark received his bachelor’s degree from Yale University and his MBA from Southern Methodist University.